Download PDF
CC BY 4.0 · Arq Neuropsiquiatr 2022; 80(09): 973-974
DOI: 10.1055/s-0042-1755213
Images in Neurology

Transient splenial lesion as late complication of COVID-19 infection

Lesão esplênica transitória como complicação tardia da infecção por COVID-19
Ali Koksal 
1   Ankara Private Bayindir Hospital, Ankara, Turkey.
,
Yasemin Ogul 
2   Duzce Public Health Center, Duzce, Turkey.
,
Veysel Ayyildiz 
3   Suleyman Demirel University, Medical Faculty, Department of Radiology, Isparta, Turkey.
,
Hayri Ogul 
4   Duzce University, Duzce, Medical Faculty, Department of Radiology, Turkey.
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

A 33-year-old woman presented with breathing discomfort, cough, and fever. The real-time reverse-transcriptase polymerase-chain-reaction (rRT-PCR) analysis was positive for coronavirus disease 2019 (COVID-19). The computed tomography (CT) scan showed ground glass opacities in lung parenchyma ([Figure 1A-C]). The patient was treated with favipiravir. One month after discharge, the magnetic resonance imaging (MRI) scan showed a lesion in the corpus callosum ([Figure 2A–B]). The imaging results were compatible with a transient splenial lesion. The patient was completely recovered after 1 month, without any specific treatment. Control MRI showed complete resolution of the lesion ([Figure 2C-D]). We thought that the splenial lesion was caused by the coronavirus infection; COVID-19 infection presenting with transient splenial lesion in an adult patient has been reported in only a few cases.[1] [2] [3]

Zoom Image
Figure 1 (A–C) Axial thorax CT during the presentation scans show ground glass opacities (circles) in both lung parenchyma.
Zoom Image
Figure 2 (A and B) One month after successful therapy, diffusion weight imaging (DWI) shows significant diffusion restriction with reduced apparent diffusion coefficient (ADC) in the lesion. (C and D) One month after first MRI scan, DWI and ADC map reveal completely resolution of the lesion.

Authors' Contributions

HO: wrote the initial draft of the manuscript; AK: contributed to interpretation of the data and assisted in the preparation of the manuscript. All authors read and approved the final version of the manuscript and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work will be appropriately investigated and resolved.




Publication History

Received: 11 November 2021

Accepted: 19 February 2022

Article published online:
09 November 2022

© 2022. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Hayashi M, Sahashi Y, Baba Y, Okura H, Shimohata T. COVID-19-associated mild encephalitis/encephalopathy with a reversible splenial lesion. J Neurol Sci 2020; 415: 116941
    CrossrefPubMedSearch in Google Scholar
  • 2 El Aoud S, Sorial D, Selmaoui A. et al. A first case of Mild Encephalitis with Reversible Splenial Lesion(MERS) as a presenting feature of SARS-CoV-2. Rev Neurol (Paris) 2021; 177 (1-2): 139-141
    CrossrefPubMedSearch in Google Scholar
  • 3 Chauffier J, Poey N, Husain M. et al. First Case of Mild Encephalopathy with Reversible Splenial Lesion in SARS-CoV-2 Infection. Infect Dis Now 2021; 51 (01) 99-101
    CrossrefPubMedSearch in Google Scholar